{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:03:28Z","timestamp":1793073808602,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Margot und Erich Goldschmidt & Peter Ren\u00e9 Jacobson-Foundation","award":["PG-23-0315-H-02"],"award-info":[{"award-number":["PG-23-0315-H-02"]}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["P500PM_217670"],"award-info":[{"award-number":["P500PM_217670"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>There is scarce long-term data on the risk of chronic kidney disease (CKD) in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD). We hypothesize that the risk of CKD in MASLD is increased and may vary with worsening histological severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nationwide matched cohort study including all Swedish adults with histologically confirmed MASLD from 1969 to 2017 (n\u00a0=\u00a011\u2009082) without prior kidney disease [simple steatosis (n\u00a0=\u00a07522), non-fibrotic metabolic dysfunction-associated steatohepatitis (n\u00a0=\u00a01257), non-cirrhotic fibrosis (n\u00a0=\u00a01692), and cirrhosis (n\u00a0=\u00a0611)]. Individuals were matched to \u22645 population comparators (n\u00a0=\u00a052\u2009645). The primary endpoint consisted of incident CKD, kidney failure with replacement therapy (KFRT; initiation of dialysis or kidney transplant) or death from kidney disease. Multivariable Cox regression was used to estimate adjusted hazard ratios (aHRs). Individuals with MASLD with at least one sibling were compared to their full siblings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over a median of 17.6 years, 878 individuals with MASLD [incidence rate (IR) 53.1\/10\u2009000 person-years] vs. 2643 comparators (IR 27.4) developed the composite CKD outcome. This was equal to one additional composite outcome event in 39 individuals with MASLD followed for ten years and corresponded to an aHR of 1.85 [95% confidence interval (CI) 1.68\u00a0\u2212\u00a02.04]. The HR increased with worsening histological severity of MASLD (Ptrend\u00a0&amp;lt; .001). Individuals with MASLD were at an almost two-fold increased hazard of CKD (aHR 1.83; 95% CI 1.66 \u2212 2.02) and three-fold increased hazard of KFRT (aHR 2.88; 95% CI 2.32 \u2212 3.57). Findings were robust and consistent across sensitivity and secondary analyses, including when individuals with MASLD were compared to their full biological siblings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Individuals with biopsy-proven MASLD were at higher risk of developing CKD compared to both the general population and siblings. Excess risks were evident across all histological stages of MASLD and increased with worsening histologic severity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfag147","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:38:59Z","timestamp":1782214739000},"source":"Crossref","is-referenced-by-count":2,"title":["Risk of CKD in biopsy-proven metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1093","author":[{"given":"Fahim","family":"Ebrahimi","sequence":"first","affiliation":[{"name":"Karolinska Institutet Department of Medical Epidemiology and Biostatistics, , Stockholm ,","place":["Sweden"]},{"name":"Basel Department of Gastroenterology and Hepatology, University Digestive Health Care Center Basel\u2013\u2013Clarunis, ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5428-0971","authenticated-orcid":false,"given":"Christian","family":"Eichhorn","sequence":"additional","affiliation":[{"name":"Basel Department of Gastroenterology and Hepatology, University Digestive Health Care Center Basel\u2013\u2013Clarunis, ,","place":["Switzerland"]},{"name":"Harvard T.H. Chan School of Public Health Department of Epidemiology, , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey G","family":"Simon","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangwei","family":"Sun","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medical Epidemiology and Biostatistics, , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-1762","authenticated-orcid":false,"given":"David","family":"Bergman","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medical Epidemiology and Biostatistics, , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole A","family":"Marxer","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medical Epidemiology and Biostatistics, , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Alkhatib","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medical Epidemiology and Biostatistics, , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soran R","family":"Bozorg","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medical Epidemiology and Biostatistics, , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-1759","authenticated-orcid":false,"given":"Hannes","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Upper GI, Karolinska University Hospital , Stockholm ,","place":["Sweden"]},{"name":"Karolinska Institutet Department of Medicine, Huddinge, , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-2024","authenticated-orcid":false,"given":"Juan J","family":"Carrero","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medical Epidemiology and Biostatistics, , Stockholm ,","place":["Sweden"]},{"name":"Stockholm Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1024-5602","authenticated-orcid":false,"given":"Jonas F","family":"Ludvigsson","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medical Epidemiology and Biostatistics, , Stockholm ,","place":["Sweden"]},{"name":"Department of Pediatrics, \u00d6rebro University Hospital , \u00d6rebro ,","place":["Sweden"]},{"name":"New York Department of Medicine, Columbia University College of Physicians and Surgeons, , NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"2026071005413942600_bib1","doi-asserted-by":"publisher","first-page":"101898","DOI":"10.1016\/j.aohep.2025.101898","article-title":"Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045","volume":"30","author":"Kan","year":"2025","journal-title":"Ann Hepatol"},{"key":"2026071005413942600_bib2","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","article-title":"Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals","volume":"107","author":"Chan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071005413942600_bib3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026071005413942600_bib4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"2026071005413942600_bib5","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s12072-019-09995-8","article-title":"Hepatocellular carcinoma and non-alcoholic fatty liver disease","volume":"13","author":"Golabi","year":"2019","journal-title":"Hepatol Int"},{"key":"2026071005413942600_bib6","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/hep.31845","article-title":"Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study","volume":"74","author":"Simon","year":"2021","journal-title":"Hepatology"},{"key":"2026071005413942600_bib7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"2026071005413942600_bib8","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"key":"2026071005413942600_bib9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"key":"2026071005413942600_bib10","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD","volume":"22","author":"Sakurai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026071005413942600_bib11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/joim.13673","article-title":"Increased risk for microvascular outcomes in NAFLD-A nationwide, population-based cohort study","volume":"294","author":"Ebert","year":"2023","journal-title":"J Intern Med"},{"key":"2026071005413942600_bib12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrneph.2017.16","article-title":"Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease","volume":"13","author":"Targher","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2026071005413942600_bib13","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jhep.2017.08.024","article-title":"Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study","volume":"67","author":"Sinn","year":"2017","journal-title":"J Hepatol"},{"key":"2026071005413942600_bib14","doi-asserted-by":"publisher","first-page":"e100005","DOI":"10.1136\/egastro-2023-100005","article-title":"Metabolic dysfunction-associated fatty liver disease increases risk of chronic kidney disease: a systematic review and meta-analysis","volume":"1","author":"Zhou","year":"2023","journal-title":"eGastroenterology"},{"key":"2026071005413942600_bib15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"2026071005413942600_bib16","doi-asserted-by":"publisher","first-page":"1433857","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"2026071005413942600_bib17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/CLEP.S191914","article-title":"Cohort profile: ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden)","volume":"11","author":"Ludvigsson","year":"2019","journal-title":"CLEP"},{"key":"2026071005413942600_bib18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/CLEP.S499859","article-title":"Cohort update: ESPRESSO (Epidemiology Strengthened by Histopathology Reports in Sweden)","volume":"17","author":"Ludvigsson","year":"2025","journal-title":"CLEP"},{"key":"2026071005413942600_bib19","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"von\u00a0Elm","year":"2014","journal-title":"Int J Surg"},{"key":"2026071005413942600_bib20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.31726","article-title":"Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement","volume":"74","author":"Hagstr\u00f6m","year":"2021","journal-title":"Hepatology"},{"key":"2026071005413942600_bib21","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"2026071005413942600_bib22","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"},{"key":"2026071005413942600_bib23"},{"key":"2026071005413942600_bib24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European Association for the Study of D, European Association for the Study of O, European Association for the Study of the L. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver. Electronic address eee","year":"2024","journal-title":"J Hepatol"},{"key":"2026071005413942600_bib25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","article-title":"Registers of the Swedish total population and their use in medical research","volume":"31","author":"Ludvigsson","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"2026071005413942600_bib26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2026071005413942600_bib27","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug"},{"key":"2026071005413942600_bib28","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"2026071005413942600_bib29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"2026071005413942600_bib30","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"2026071005413942600_bib31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/joim.12964","article-title":"Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study","volume":"286","author":"Park","year":"2019","journal-title":"J Intern Med"},{"key":"2026071005413942600_bib32","doi-asserted-by":"publisher","first-page":"101506","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab"},{"key":"2026071005413942600_bib33","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"2026071005413942600_bib34","doi-asserted-by":"publisher","first-page":"e3957","DOI":"10.1210\/clinem\/dgab425","article-title":"New nonalcoholic fatty liver disease and fibrosis progression associate with the risk of incident chronic kidney disease","volume":"106","author":"Zuo","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071005413942600_bib35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction-associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"key":"2026071005413942600_bib36","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41581-023-00741-w","article-title":"Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease","volume":"19","author":"Mitrofanova","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"2026071005413942600_bib37","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.1152\/ajpendo.00179.2022","article-title":"Obesity and chronic kidney disease","volume":"324","author":"Jiang","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026071005413942600_bib38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/biology10010018","article-title":"Oxidative stress and inflammation in renal and cardiovascular complications of diabetes","volume":"10","author":"Charlton","year":"2020","journal-title":"Biology"},{"key":"2026071005413942600_bib39","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1042\/CS20171459","article-title":"A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes","volume":"132","author":"Jha","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"2026071005413942600_bib40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.atherosclerosis.2020.03.009","article-title":"Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease","volume":"299","author":"Tucker","year":"2020","journal-title":"Atherosclerosis"},{"key":"2026071005413942600_bib41","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s12072-020-10063-9","article-title":"Portal inflammation predicts renal dysfunction in patients with nonalcoholic fatty liver disease","volume":"14","author":"An","year":"2020","journal-title":"Hepatol Int"},{"key":"2026071005413942600_bib42","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.pmedr.2023.102536","article-title":"The association of systemic inflammatory biomarkers with non-alcoholic fatty liver disease: a large population-based cross-sectional study","volume":"37","author":"Sun","year":"2024","journal-title":"Prevent Med Rep"},{"key":"2026071005413942600_bib43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41581-021-00519-y","article-title":"Association of metabolic dysfunction-associated fatty liver disease with kidney disease","volume":"18","author":"Wang","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2026071005413942600_bib44","doi-asserted-by":"publisher","first-page":"2482158","DOI":"10.1080\/21505594.2025.2482158","article-title":"Gut microbiome composition and metabolic activity in metabolic-associated fatty liver disease","volume":"16","author":"Zhang","year":"2025","journal-title":"Virulence"},{"key":"2026071005413942600_bib45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.gastha.2023.09.008","article-title":"Advanced fibrosis in metabolic dysfunction-associated steatotic liver disease is independently associated with reduced renal function","volume":"3","author":"Villarroel","year":"2024","journal-title":"Gastro Hep Adv"},{"key":"2026071005413942600_bib46","doi-asserted-by":"publisher","first-page":"e16010","DOI":"10.1111\/liv.16010","article-title":"PNPLA3 variation and kidney disease","volume":"45","author":"Mantovani","year":"2025","journal-title":"Liver Int"},{"key":"2026071005413942600_bib47","doi-asserted-by":"publisher","first-page":"6406","DOI":"10.3390\/ijms26136406","article-title":"Polymorphism\u2019s MBOAT7 as risk and MTARC1 as protection for liver fibrosis in MASLD","volume":"26","author":"Rocha","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026071005413942600_bib48","doi-asserted-by":"publisher","first-page":"e010912","DOI":"10.1161\/CIRCOUTCOMES.124.010912","article-title":"Risk of major adverse cardiovascular outcomes in families with MASLD: a population-based multigenerational cohort study","volume":"17","author":"Ebrahimi","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026071005413942600_bib49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ueg2.12761","article-title":"Metabolic dysfunction-associated steatotic liver disease and pancreatic disease-a population-based nationwide cohort and sibling-controlled study","volume":"13","author":"Vujasinovic","year":"2025","journal-title":"UEG J"},{"key":"2026071005413942600_bib50","doi-asserted-by":"publisher","first-page":"101358","DOI":"10.1016\/j.jhepr.2025.101358","article-title":"Liver fibrosis progression analyzed with AI predicts renal decline","volume":"7","author":"Sun","year":"2025","journal-title":"JHEP Rep"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag147\/68590220\/gfag147.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag147\/68590220\/gfag147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:41:48Z","timestamp":1783676508000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article\/doi\/10.1093\/ndt\/gfag147\/8715013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag147","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"gfag147"}}